DEXCOM INC — Director's Dealing 2019

Mar 27, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2019-03-25

Reporting Person: DOUBLEDAY RICHARD (EVP Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-25	Common Stock	S	616	$126.4691	Disposed	13496	Indirect
2019-03-25	Common Stock	S	1400	$127.7746	Disposed	12096	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	72570	Direct

Footnotes

F1: On June 1, 2018, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: This transaction was executed in multiple trades at prices ranging from $126.01 to $127.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3: Included in this number are 51,203 unvested restricted stock units, 16,365 of which were granted on March 8, 2019 and shall vest through March 8, 2022, 25,668 of which were granted on March 8, 2018 and shall vest through March 8, 2021 and 9,170 of which were granted on March 8, 2017 and shall vest through March 8, 2020.

F4: This transaction was executed in multiple trades at prices ranging from $127.01 to $128.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.